What is the HLS.TO share price today?

This page shows the latest available HLS Therapeutics Inc. (HLS.TO) price with its change against the prior close. Values are delayed or previous-close, not real-time.

Where is HLS Therapeutics Inc. listed?

HLS Therapeutics Inc. trades on the Toronto Stock Exchange under the symbol HLS.TO, ISIN CA40390B1094.

How large is HLS Therapeutics Inc.?

Its market capitalisation is approximately 121.97M CAD, based on the latest available price and share count from our data provider.

Toronto Stock Exchange (TSX) · HLS.TO · ISIN CA40390B1094

HLS Therapeutics Inc.

3.91 CAD

−0.08(−2.01%)

Previous close · Sep 18, 16:00 ET

Data last updated: Sep 18, 16:00 ET (20 h ago)· Delayed exchange data

HLS Therapeutics Inc. (HLS.TO) trades on the Toronto Stock Exchange and operates in the Drug Manufacturers - Specialty & Generic industry. Its market capitalisation is approximately 121.97M CAD. The company reports around 85 employees. Its ISIN is CA40390B1094. This page shows the latest available price, the day and 52-week ranges and an interactive chart. Quotes are delayed and are not intended for order execution.

Checking today's session…

Key facts

Exchange

Toronto Stock Exchange (TSX)

ISIN

CA40390B1094

Sector

Healthcare

Industry

Drug Manufacturers - Specialty & Generic

Country

Market cap

122.28M CAD

Employees

Previous close

3.99 CAD

Day range

3.91 – 4.02

52-week range

0.00 – 5.76

Volume

27.49K

50-day average

3.98 CAD

200-day average

4.41 CAD

Asset type

Equity

About HLS Therapeutics Inc.

HLS Therapeutics Inc. operates as a specialized pharmaceutical firm, concentrating on the acquisition and commercialization of medicinal products, primarily within the niche central nervous system (CNS) and cardiovascular (CV) sectors. Its reach extends across Canada, the United States, and international markets. The company's core product lineup includes Clozaril, an atypical antipsychotic used in the treatment of schizophrenia; Vascepa, an icosapent ethyl capsule formulation; and PERSERIS, an injectable risperidone product for treating schizophrenia. Additionally, HLS offers MyCare psychiatry laboratory assays and MyCare Insite tests for point-of-care therapeutic drug-level monitoring. Furthermore, the company possesses U.S. marketing privileges for Absorica, a commercial-stage dermatology solution, and Canadian rights for Trinomia, a cardiovascular therapeutic. It also manages a portfolio of royalty interests from four distinct healthcare products. Founded in 2018, HLS Therapeutics Inc. is based in Etobicoke, Canada.

Company website

Frequently asked

What is the HLS.TO share price today?: This page shows the latest available HLS Therapeutics Inc. (HLS.TO) price with its change against the prior close. Values are delayed or previous-close, not real-time.
Where is HLS Therapeutics Inc. listed?: HLS Therapeutics Inc. trades on the Toronto Stock Exchange under the symbol HLS.TO, ISIN CA40390B1094.
How large is HLS Therapeutics Inc.?: Its market capitalisation is approximately 121.97M CAD, based on the latest available price and share count from our data provider.

All HLS Therapeutics Inc. data comes from exchange and provider feeds for the Toronto Stock Exchange and is published for information, not as investment advice.

Real-time quotes are not licensed; prices are delayed or previous close, so they may lag the market by 15 minutes or a full session. Information only, not for trading. Where a figure is not covered by our licensed sources, the page says so rather than showing a substitute.